The present invention relates to the use of certain novel compositions from clary sage (Salvia sclarea) which are inhibitors of nuclear factor kappa B (NF-.kappa.B), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from clary sage for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an inhibitor of oxidative stress (activation of Nerf2), NF-.kappa.B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compositions from clary sage useful to inhibit cell proliferation and for the induction of apoptosis.